Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published online before print June 6, 2008, 10.1148/radiol.2482072039
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2482072039v1
248/2/643    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Ohno, Y.
Right arrow Articles by Sugimura, K.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ohno, Y.
Right arrow Articles by Sugimura, K.
Related Collections
Right arrowRelated Article
(Radiology 2008;248:643-654.)
© RSNA, 2008

Thoracic Imaging

Non–Small Cell Lung Cancer: Whole-Body MR Examination for M-Stage Assessment—Utility for Whole-Body Diffusion-weighted Imaging Compared with Integrated FDG PET/CT1

Yoshiharu Ohno, MD, PhD, Hisanobu Koyama, MD, Yumiko Onishi, MD, Daisuke Takenaka, MD, Munenobu Nogami, MD, Takeshi Yoshikawa, MD, Sumiaki Matsumoto, MD, Yoshikazu Kotani, MD, and Kazuro Sugimura, MD

1 From the Department of Radiology (Y. Ohno, H.K., D.T., T.Y., S.M., K.S.) and Division of Cardiovascular and Respiratory Medicine, Department of Internal Medicine (Y.K.), Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan; Division of Image-Based Medicine, Institute of Biomedical Research and Innovation, Kobe, Japan (Y. Onishi, M.N.); and Department of Radiology, Konan Hospital, Kobe, Japan (T.Y.). From the 2007 RSNA Annual Meeting. Received November 22, 2007; revision requested January 31, 2008; revision received February 10; accepted March 5; final version accepted March 18. Supported in part by Eizai, Philips Medical Systems, and the Knowledge Cluster Initiative of the Ministry of Education, Culture, Sports, Science and Technology, Japan. Address correspondence to Y. Ohno (e-mail: yosirad{at}kobe-u.ac.jp).

Purpose: To prospectively and directly compare the capability of whole-body diffusion-weighted (DW) imaging, whole-body magnetic resonance (MR) imaging with and that without DW imaging, and integrated fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) for M-stage assessment in non–small cell lung cancer (NSCLC) patients.

Materials and Methods: The institutional review board approved this study; informed consent was obtained from patients. A total of 203 NSCLC patients (109 men, 94 women; mean age, 72 years) prospectively underwent whole-body DW imaging, whole-body MR imaging, and FDG PET/CT. Final diagnosis of the M-stage in each patient was determined on the basis of results of all radiologic and follow-up examinations. Two chest radiologists and two nuclear medicine physicians independently assessed all examination results and used a five-point visual scoring system to evaluate the probability of metastases. Final diagnosis based on each of the methods was made by consensus of two readers. Receiver operating characteristic (ROC) analysis was used to compare the capability for M-stage assessment among whole-body DW imaging, whole-body MR imaging with and that without DW imaging, and PET/CT on a per-patient basis. Sensitivity, specificity, and accuracy were compared with the McNemar test.

Results: Area under ROC curve (Az) values of whole-body MR imaging with DW imaging (Az = 0.87, P = .04) and integrated FDG PET/CT (Az = 0.89, P = .02) were significantly larger than that of whole-body DW imaging (Az = 0.79). Specificity and accuracy of whole-body MR imaging with (specificity, P = .02; accuracy, P < .01) and that without DW imaging (specificity, P = .02; accuracy, P = .01) and integrated FDG PET/CT (specificity, P < .01; accuracy, P < .01) were significantly higher than those of whole-body DW imaging.

Conclusion: Whole-body MR imaging with DW imaging can be used for M-stage assessment in NSCLC patients with accuracy as good as that of PET/CT.

© RSNA, 2008


Related Article

Non–Small Cell Lung Cancer Staging: Efficacy Comparison of Integrated PET/CT versus 3.0-T Whole-Body MR Imaging
Chin A Yi, Kyung Min Shin, Kyung Soo Lee, Byung-Tae Kim, Hojoong Kim, O Jung Kwon, Joon Young Choi, and Myung Jin Chung
Radiology 2008 248: 632-642. [Abstract] [Full Text] [PDF]





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
RADIOLOGY RADIOGRAPHICS RSNA JOURNALS ONLINE
Copyright © 2008 by the Radiological Society of North America.